Health
First in Human Study with Novel Antisense Oligonucleotide – EurekAlert
A single intravenous dose of MRG-110, an anti-microRNA drug, significantly reduced miR-92a levels in the blood of healthy humans.
IMAGE: focuses on cutting-edge basic research, therapeutic applications, and drug development using nucleic acids or related compounds to alter gene expression.
view more
Credit: Mary Ann Liebert, Inc., publishers
New Rochelle, NY, August 11, 2020–A single intravenous dose of MRG-110, an anti-microRNA drug, significantly reduced miR-92a levels in the blood of healthy humans. Inhibition of miR-92a has shown beneficial effects in animal models, including improved vascularization after myocar…
-
Business13 hours agoWhy did this ASX 200 healthcare stock crash 14% yesterday?
-
General21 hours agoRussia launches hundreds of drones and missiles against Ukraine in fresh attack
-
Business16 hours agoOwn Xero shares? Here are 3 key takeaways from its AGM
-
General13 hours agoPatients speak out after Brisbane doctor accused of ‘excessive’ pap smears, kissing woman on lips